Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-06-18
- Target Recruit Count
- 65
- Registration Number
- NCT06856213
- Locations
- 🇪🇸
Hospital Universitario Marqués de Valdecilla (Santander), Santander, Cantabria, Spain
🇪🇸Centro Oncológico de Galicia (La Coruña), A coruña, La Coruña, Spain
🇪🇸Hospital Infanta Leonor (Madrid), Vallecas, Madrid, Spain
Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)
- Conditions
- Carcinoma
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-03-31
- Target Recruit Count
- 34
- Registration Number
- 2024-516779-33-00
- Locations
- 🇪🇸
Ajuntament De L Hospitalet De Llobregat, L'hospitalet De Llobregat, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain
🇪🇸Hospital Universitari Vall D Hebron, Barcelona, Spain
Spanish Study for Molecular Characterization of Thyroid Carcinoma
- Conditions
- Medullary Thyroid CarcinomaDifferentiated Thyroid Carcinoma
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-04-20
- Target Recruit Count
- 150
- Registration Number
- NCT04970134
- Locations
- 🇪🇸
Hospital Universitario Durán i Reinals, L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸Fundació Althaia, Manresa, Barcelona, Spain
🇪🇸Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, Spain
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-23
- Target Recruit Count
- 531
- Registration Number
- NCT04672772
- Locations
- 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Andalucia, Spain
🇪🇸Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
🇪🇸Hospital Universitario Virgen de Valme, Sevilla, Andalucia, Spain
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
- Conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Nivolumab + Paclitaxel
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2025-06-26
- Target Recruit Count
- 141
- Registration Number
- NCT04282109
- Locations
- 🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea, San Sebastián, San Sebastían, Spain
🇪🇸Centro Oncoloxico de Galicia, A Coruña, Spain
- Prev
- 1
- 2
- Next